DOCSLIB.ORG

List of New Drugs Approved in India from 1971 to 1980

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of New Drugs Approved in India from 1971 to 1980 LIST OF NEW DRUGS APPROVED IN INDIA FROM 1971 TO 1980 S.No Name of Drug Pharmacological action/ Date of Indication Approval 1 2-Thymyl-oxy-methyl January-1971 glyoxalidine Hydrochloride 0.05 + Buffered Aqueous Vehicle- q.s (Nasal Spray) 2 Hamycin Glycerine (300,000 January-1971 Units/ml) Suspension 3 Ferrous Sulphate 150mg January-1971 Sustained Release 4 Hydroxyurea USP 500mg Anti neoplastic agent. January-1971 Capsule 5 Prednisolone Stearoylglucolate February-1971 (6.65mg) Tablet, (1.9g) Ophthalmic Ointment, (1.9g) Cream & Ointment 6 Hydroflumethiazide 25mg March-1971 Tablet 7 Chlorphenoxamine Hcl 12mg March-1971 Tablet 8 Epsilon Caproic Acid March-1971 250mg/ml Injection 9 Ibuprofen 200mg Tablet Anti rheumatic. March-1971 10 Mebeverine Hcl 50mg Tablet Musculo tropic spasmolytic. March-1971 11 Panchronium Bromide 4mg/ml Muscular relaxanting agent. April-1971 Injection (i.v) 12 Ephedrine Sulphide 75mg May-1971 Sustained Release Capsule. 13 L-Dihydroxyphenylalanine May-1971 500mg Capsule/Tablet 14 Rifampicin 450mg Anti T.B drug June-1971 15 Quinestrol 25mcg Tablet Oestrogenic steroid. July-1971 16 Ketamine Hydrochloride Anaesthetic agent. August-1971 17 Ibuprofen 200 mg Tablet September-1971 18 Rifampicin 150mg/300mg September-1971 Capsule 19 Glybenclamide 5mg Tablet September-1971 20 Mebeverine Hcl 100mg Tablet Musculo tropic spasmolytic. October-1971 21 P-Aminomethyl Benzoic Acid October-1971 50mg/5ml Ampoule 22 Lactobacillus Sporogenes October-1971 50/100million Tablet 23 Salbutamol Sulphate B.P Bronchial asthma. October-1971 24 Yeast Tannic Acid Compound Anti-diarrhoeal agent. October-1971 25 Cephalexin Broad spectrum antibiotic. October-1971 26 Pheniramine Maleate Retard November-1971 Tablet 27 Propranalol Hcl 10mg Tablet November-1971 & (1ml) Injection 28 Tetranicotinoyl Fructose November-1971 29 Testolactone November-1971 30 Spiramycin Injection November-1971 31 Tetranicotinoyl Fructose December-1971 250mg Tablet 32 Prednisolone IP 10 mg Retard December-1971 Tablet 33 Clopidol (For Veterinary) Coccodiosis. January-1972 34 3,5 - Dinitro-O-Toluamide (For January-1972 Veterinary) 35 Fenfluramine Hcl Anti-obesity drug. January-1972 36 Testolactone 50mg Tablet March-1972 37 Fenfluramine Hcl 20mg Tablet April-1972 38 Marek's Disease Vaccine April-1972 T.H.U Living (For Veterinary) 39 Ferric Sodium Citrate April-1972 40 Prothionamide 125mg Tablet June-1972 41 Prothionamide B.P. Anti T.B. June-1972 42 Sarcolysin I.P. Anti cancer. June-1972 43 Pyrantel Pamoate USP Anthelmintic. July-1972 44 Doxepin Hydrochloride Psychotic drug. July-1972 45 Biperiden Hydrochloride Parkinsonism. July-1972 46 Marcaine 0.25% with & September-1972 without adrenaline and Marcaine 0.5% with or without adrenaline 47 Doxepine Hydrochloride September-1972 10mg/25mg/50mg Tablet/Dragee/Capsule 48 Bupivacaine Hydrochloride Anaesthetic. September-1972 49 Fluphenazine Decanoate Anti-psychotic. September-1972 50 2-Bromo-2-Nitropropan-1,3- Preservative. September-1972 diol 51 Propranolol Hcl (10mg/40mg) October-1972 Tablet & (1mg/ml) Injection 52 Chloramphenicol 500mg October-1972 Capsule 53 Biperiden Lactate 5mg/ml Parkinsonism. October-1972 Ampoule 54 Cyclandelate Vasodilating agent. October-1972 55 Theophylline Ethanoate of November-1972 Piperazine (0.25gm) Tablet & (0.125gm/ml) Syrup 56 i)Betadine Solution containing November-1972 10% of Povidone Iodine, ii)Betadine Gargle containing 0.5% of Povidone Iodine, iii)Betadine Ointment containing 10% of Povidone Iodine. 57 Ferrous Sulphate 160mg Slow November-1972 Release Tablet 58 Lithium Carbonate 250mg November-1972 Capsule 59 Oxyclozanide (For Veterinary) November-1972 60 Sodium Cromoglucolate Anti-asthmatic drug. November-1972 61 Fenfluramine Hcl 20mg Tablet December-1972 62 Doxycycline Hcl (eq. to December-1972 Doxycycline base) 100mg Capsule 63 Isopropyl Thioimidazolidine December-1972 5mg Tablet 64 Lincomycin Hydrochloride December-1972 500mg Capsule 65 Mitomycin-C 2mg/Vial December-1972 66 Amantadine Hydrochloride Parkinsonism. December-1972 67 Daunorubicin Anticancer. December-1972 68 Cyproheptadine Hcl 4mg January-1973 Tablet 69 Cyclandelate 200mg Tablet February-1973 70 Xantinol Nicotinate 500mg February-1973 Sustained Release Tablet 71 Ethacrynic Acid USP Non-thiazide saluretic diuretic. February-1973 25mg/50mg Tablet 72 Salbutamal Sulphate 4mg February-1973 Tablet 73 Beclomethasone Dipropionate Topical corticosteroid. February-1973 B.P. 74 Parbendazole (For Veterinary) Treatment of Helmenthiasis. February-1973 75 Ethacridine Lactate Anti-diarrhoeal agent. February-1973 76 Stanozolol 2mg Tablet March-1973 77 Oxyfedrine Coronary vasodilator. April-1973 78 Trifluperidol Hcl 5mg/5ml Neuroleptic agent. May-1973 Oral Liquid 79 Trifluperidol Hcl 1mg/ml Neuroleptic agent. May-1973 Injection 80 Trifluperidol Hcl Neuroleptic agent. May-1973 0.25mg/0.5mg Tablet 81 Polyglycolic Acid Sutures May-1973 82 L-Asparaginase Anticancer. May-1973 83 Lincomycin Hcl (eq. to June-1973 Lincomycin base) 250mg/5ml Syrup 84 Prenylamine Lactate 60mg June-1973 Tablet 85 Oxprenolol Hydrochloride Beta-blocker. June-1973 86 Furaltadone June-1973 87 Nitrazepam Epileptic. June-1973 88 Tetramisole Hydrochloride July-1973 30% (For Veterinary) 89 Oxyfedrine (8mg) Tablet, Coronary Vasodilator- for July-1973 (10mg) Solution, (2mg/ml) Angina pectoris, Myocardial Injection infarction and Coronary insufficiency. 90 Furaltadone 20% w/w Powder Poultry diseases only. August-1973 (For Veterinary) 91 Alphachymotrypsin 5mg/vial For use of eye specialists only. August-1973 Injection 92 Carbenicillin Disodium Antibiotic. August-1973 1gm/vial Injection 93 Pentazocine base (as August-1973 Hydrochloride) 50mg Tablet 94 Marantel Tartrate August-1973 95 Nitrazepam 5mg Tablet September-1973 96 Fluphenazine Decanoate September-1973 2mg/ml Injection 97 Nitroxazepine Hydrochloride September-1973 25mg/2ml Injection 98 Lorazepam Psychiatric drug. September-1973 99 Pindolol Tablet Beta blocking agent September-1973 100 Nitroxazepine Hydrochloride October-1973 25mg Tablet 101 Pindolol 5mg Tablet November-1973 102 Aprotinin Acute Pancreatitis. November-1973 103 Practolol Cardiac Drug. November-1973 104 Malathion 1% Dusting Powder December-1973 105 Lorazepam 1mg/2mg Tablet Psychiatric drug. December-1973 106 Bleomycin Anticancer. December-1973 107 Carbenoxolone Sodium Gastric ulcer. December-1973 108 Betamethasone-17-Benzoate Topical anti-inflammatory December-1973 steroid. 109 Thiophanate (For Veterinary) Anthelmintic. December-1973 110 Practolol BP 100mg Tablet January-1974 111 Aprotinin 100,000 KIU/5ml & January-1974 200,000 KIU/10ml Injection 112 Carbenoxolone Sodium 50mg January-1974 Tablet 113 Meglumine iocarmate X-ray contrast media. February-1974 114 Clomiphene Citrate B.P 50mg Fertility drug- induction of February-1974 Tablet ovulation in patients with persistant ovulatory dysfunction who desire pregnancy. 115 Tinidazole 150mg Tablet Trichomonial agent- for the February-1974 treatment of trichomoniasis & intestinal amoebiasis. 116 Nitrofurantoin BP March-1974 100mcg/200mcg Sensitive Disc 117 Beclomethasone Dipropionate April-1974 0.025% Cream & Ointment 118 d-Norgestrel 0.03mg Coated Oral contraceptive. April-1974 Tablet 119 Epicillin (6-aminopenicillanic Antibiotic- For the treatment as May-1974 acid) 250mg/500mg Capsule respiratory tract, G.I. Tract and genitourinary tract infections. 120 Sodium Fusidate 20mg/gm Antibiotic- for the treatment of May-1974 Ointment staphylococcal infections such as abscesses boils, carbuncles, varicose ulcer,eczema. 121 Tretinoin 0.05%/20gm Topical acne therapy- For the July-1974 Vanishing Cream treatment of Acne vulgaris. 122 Tretinoin 0.05%/50ml Lotion July-1974 123 Tretinion 0.05% Swab July-1974 124 Tretinion 0.05% Cream July-1974 125 Mesterolone 10mg Tablet Oral androgen- In the treatment July-1974 of potency disturbances, infertility and hypogonadism only. 126 D-Pencillamine 300mg Tablet Metalic poisoning- In the July-1974 treatment of metalic poisoning and Wilson's disease. 127 d-Norgestrel 0.03mg Tablet August-1974 128 Pimozide Neuroleptic and anti psychotic August-1974 agent- In the treatment of chronic Schizophrenia. 129 Lidoflazine 60mg Tablet Coronary Vasodilator- November-1974 Indicated in the treatment as Ischaemic heart disease and prophylaxis after treatment of myocardial infarction. 130 Isoptin Hydrochloride September-1974 5mg/2ml Injection 131 Oxolinic acid Urinary antibacterial- For the September-1974 treatment of acute & chronic urinary tract infections. 132 Salbutamol Sulphate 2mg/5ml October-1974 Elixir 133 Bupivacaine hydrochloride December-1974 10mg/ml Hyperbaric Solution 134 Pimozide 1mg/4mg Tablet December-1974 135 Mebendazole 100mg Tablet Broad spectrum anthelmentic- December-1974 For the treatment of enterobiasis as carriasis, trichuriasis ancyclostomiasis, strongylodiasis (pin warm, large round warm, whip warm, hooks warm and thread warm. 136 Miconazole 2% Cream Topical antifungal and anti December-1974 bacterial agent- for the treatment of onychomycosis, dermatophytosis and vulvovaginitis. 137 Desamino-oxytocin Indicated in the treatment of December-1974 induction of labour for various reasons for adequate uterine action. 138 Virginiamycin obtained from Antibiotic- Indicated for February-1975 streptomyces virginiae growth propotion in poultry (Veterinary) pigs and for prevention & treatment of swine dysentry. 139 Extract of Centella Asiatica Indicated in the treatment as February-1975 ulcers, burns, skin grafts, keloids, bed sore etc. 140 Clonidine Hcl Antihypertensive agent- February-1975
Load more

Recommended publications
  • R&D UNICANCER Annual Report 2016
    Going further, innovating together R&D UNICANCER Annual Report 2016 Summary Presentation and organisation Regulatory affairs, pharmaco- PAGE 01 vigilance, quality assurance – Ensuring quality and safety 2016 clinical activity in clinical trials. PAGE 08 PAGE 25 Expert groups Epidemiological Strategy and PAGE 16 Medical Economics (ESME) 2016 publications Programme – Harnessing PAGE 21 real-life data in oncology to improve patient care. Clinical operations PAGE 27 PAGE 23 Development Biological Resource and partnerships – Centre (BRC) Optimising collaborations PAGE 24 to foster innovation PAGE 30 Research in the FCCC PAGE 32 Appendices PAGE 33 Contacts, Follow us PAGE 45 GOING FURTHER, INNOVATING TOGETHER R&D ANNUAL REPORT 2016 Presentation and organisation UNICANCER, a major French player in oncology, Acteur majeur de la cancérologie française, groups together 20 French Comprehensive Cancer UNICANCER regroupe les 20 Centres de lutte contre Centers (FCCC). They are private, non-profit health la cancérologie (CLCC), établissements de santé establishments exclusively dedicated to care, research privés à but non lucratif exclusivement dédiés aux and education in cancer. UNICANCER’s R&D soins, à la recherche et à l’enseignement en cancéro- department is the driving force of UNICANCER’s logie. R&D UNICANCER en tant que promoteur research and, as an academic sponsor, it works direc- aca démi que, travaille en direct avec les unités de tly with the research units of the FCCC and other recherche des CLCC et d’autres établissements health establishments (university hospitals, hospitals de santé (CHU, CH, cliniques) en France et à l’inter- and clinics) in France and abroad. The mission of R&D national.
    [Show full text]
  • WO 2018/009638 Al 11 January 2018 (11.01.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/009638 Al 11 January 2018 (11.01.2018) W !P O PCT (51) International Patent Classification: Published: C07D 413/14 (2006.01) A61K 31/553 (2006.01) — with international search report (Art. 21(3)) C07D 403/14 (2006.01) A61P 35/00 (2006.01) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US20 17/040866 amendments (Rule 48.2(h)) (22) International Filing Date: 06 July 2017 (06.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/359,001 06 July 2016 (06.07.2016) 62/454,163 03 February 2017 (03.02.2017) (71) Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; Office Of Technology Tran s fer, 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109-2590 (US). (72) Inventors: ROSS, Brian, D.; 2410 Foxway, Ann Arbor, MI 48105 (US). VAN DORT, Marcian; 643 Dornoch Dr., Ann Arbor, MI 48103 (US). (74) Agent: NAPOLI, James, J.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Rediscovery of Fexinidazole
    New Drugs against Trypanosomatid Parasites: Rediscovery of Fexinidazole INAUGURALDISSERTATION zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Marcel Kaiser aus Obermumpf, Aargau Basel, 2014 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Dieses Werk ist unter dem Vertrag „Creative Commons Namensnennung-Keine kommerzielle Nutzung-Keine Bearbeitung 3.0 Schweiz“ (CC BY-NC-ND 3.0 CH) lizenziert. Die vollständige Lizenz kann unter creativecommons.org/licenses/by-nc-nd/3.0/ch/ eingesehen werden. 1 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel auf Antrag von Prof. Reto Brun, Prof. Simon Croft Basel, den 10. Dezember 2013 Prof. Dr. Jörg Schibler, Dekan 2 3 Table of Contents Acknowledgement .............................................................................................. 5 Summary ............................................................................................................ 6 Zusammenfassung .............................................................................................. 8 CHAPTER 1: General introduction ................................................................. 10 CHAPTER 2: Fexinidazole - A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness ........ 26 CHAPTER 3: Anti-trypanosomal activity of Fexinidazole – A New Oral Nitroimidazole Drug Candidate for the Treatment
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Reseptregisteret 2013–2017 the Norwegian Prescription Database
    LEGEMIDDELSTATISTIKK 2018:2 Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Christian Berg Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Utgitt av Folkehelseinstituttet/Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2018 Tittel/Title: Legemiddelstatistikk 2018:2 Reseptregisteret 2013–2017 / The Norwegian Prescription Database 2013–2017 Forfattere/Authors: Christian Berg, redaktør/editor Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon/Contact information: Folkehelseinstituttet/Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8082-926-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2013–2017 [The Norwegian Prescription Database 2013–2017] Legemiddelstatistikk 2018:2, Oslo, Norge: Folkehelseinstituttet, 2018. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian Prescription Database 2005–2009.
    [Show full text]
  • National Code Item Name 1
    NATIONAL CODE ITEM NAME 1 CARDIOVASCULAR SYSTEM 1A Positive inotropic drugs 1AA Digtalis glycoside 02-01-00001 Digoxin 62.5mcg Tablet 800,000 02-01-00002 Digitoxin 100mcg Tablet 800,000 02-01-00003 Digoxin 125 mcg Tablet 800,000 02-01-00004 Digoxin 250 mcg Tablet 15,000,000 02-01-00005 Digoxin 50mcg /ml PG Elixir 800,000 02-01-00006 Digoxin 250 mcg/ml inj (2ml) Ampoule 800,000 1AB PHOSPHODIESTERASE INHIBITORS 02-01-00007 Enoximone 5mg/1ml inj (20ml) Ampoule 800,000 1B DIURETICS 02-01-00008 Amiloride Hcl 5mg + Hydrochlorthiazide 50mg Tablet 50,000,000 02-01-00009 Bumetanide 1 mg Tablet 800,000 02-01-00010 Chlorthalidone 50mg Tablet 2,867,000 02-01-00011 Ethacrynic acid 50mg as sodium salt inj (powder for reconstitution) Vial 800,000 02-01-00012 Frusemide 20mg/2ml inj Ampoule 6,625,000 02-01-00013 Frusemide 10mg/ml,I.V.infusion inj (25ml) Ampoule 800,000 02-01-00014 Frusemide 40mg Tablet 20,000,000 02-01-00015 Frusemide 500mg Scored Tablet 800,000 02-01-00016 Frusemide 1mg/1ml Oral solution peadiatric Liquid 800,000 02-01-00017 Frusemide 4mg/ml Oral Solution 800,000 02-01-00018 Frusemide 8mg/ml oral Solution 800,000 02-01-00019 Hydrochlorothiazide 25mg Tablet 800,000 02-01-00020 Hydrochlorothiazide 50mg Tablet 950,000 02-01-00021 Indapamide 2.5mg Tablet 800,000 02-01-00022 Indapamide 1.5mg S/R Coated Tablet 800,000 02-01-00023 Spironolactone 25mg Tablet 7,902,000 02-01-00024 Spironolactone 100mg Tablet 11,451,000 02-01-00025 Xipamide 20mg Tablet 800,000 1C BETA-ADRENOCEPTER BLOCKING DRUGS 02-01-00026 Acebutolol 100mg Tablet 800,000 02-01-00027 Acebutolol 200mg Tablet 800,000 02-01-00028 Atenolol 100mg Tablet 120,000,000 02-01-00029 Atenolol 50mg Tablet or (scored tab) 20,000,000 02-01-00030 Atenolol 25mg Tablet 1,483,000 02-01-00031 Bisoprolol fumarate 5mg Scored Tablet 800,000 02-01-00032 Bisoprolol fumarate 10mg Scored Tablet 800,000 02-01-00033 Carvedilol 6.25mg Tablet 800,000 02-01-00034 Carvedilol 12.5mg Tablet 800,000 02-01-00035 Carvedilol 25mg Tablet 800,000 02-01-00036 Esmolol Hcl 10mg/ml I.V.
    [Show full text]
  • The Effects of Adrenergic Amines and Theophylline On
    THE EFFECTS OF ADRENERGIC AMINES AND THEOPHYLLINE ON CONTRACTILE FORCE AND CYCLIC AMP by Terry T. Martinez M.S., Purdue University, U.S.A. 1970 B.S., Purdue University, U.S.A. 1969 A THESIS SUBMITTED IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE in the Division of Pharmacology of the Faculty of Pharmaceutical Sciences We accept this thesis as conforming to the required standard. THE UNIVERSITY OF BRITISH COLUMBIA October, 1975 In presenting this thesis in partial fulfilment of the requirements for an advanced degree at the University of British Columbia, I agree that the Library shall make it freely available for reference and study. I further agree that permission for extensive copying of this thesis for scholarly purposes may be granted by the Head of my Department or by his representatives. It is understood that copying or publication of this thesis for financial gain shall not be allowed without my written permission. Department of Pharmaceutical Sciences The University of British Columbia 2075 Wesbrook Place Vancouver, Canada V6T 1W5 Date October 14, 1975 ABSTRACT Time response studies of the effects of norepinephrine and phenylephrine revealed that both agonists caused an increase in cyclic AMP levels prior to increases in contractile force. Norepinephrine caused a nearly six fold increase in cyclic AMP, whereas phenylephrine produced only a 50% increase in the nucleo• tide. Pretreatment with reserpine did not affect the norepineph• rine cyclic AMP response; however, the phenylephrine cyclic AMP response was abolished. Reserpine pretreatment did not significant• ly affect the contractile responses of either amine.
    [Show full text]
  • WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/107 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A 61 47/10 (2006.0V) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2012/034361 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 20 April 2012 (20.04.2012) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/480,259 28 April 201 1 (28.04.201 1) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant (for all designated States except US): BOARD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, OF REGENTS, THE UNIVERSITY OF TEXAS SYS¬ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, TEM [US/US]; 201 West 7th St., Austin, TX 78701 (US).
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research
    Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Garabedian, Laura Faden. 2013. Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research. Doctoral dissertation, Harvard University. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11156786 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research A dissertation presented by Laura Faden Garabedian to The Committee on Higher Degrees in Health Policy in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Health Policy Harvard University Cambridge, Massachusetts March 2013 © 2013 – Laura Faden Garabedian All rights reserved. Professor Stephen Soumerai Laura Faden Garabedian Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research Abstract This dissertation consists of two empirical papers and one methods paper. The first two papers use quasi-experimental methods to evaluate the impact of universal health insurance reform in Massachusetts (MA) and Thailand and the third paper evaluates the validity of a quasi- experimental method used in comparative effectiveness research (CER). My first paper uses interrupted time series with data from IMS Health to evaluate the impact of Thailand’s universal health insurance and physician payment reform on utilization of medicines for three non-communicable diseases: cancer, cardiovascular disease and diabetes.
    [Show full text]
  • Hexoprenaline: Β-Adrenoreceptor Selectivity in Isolated Tissues from the Guinea-Pig
    Clinical and Experimental Pharmacology and Physiology (1975) 2, 541-547. Hexoprenaline: p-adrenoreceptor selectivity in isolated tissues from the guinea-pig Stella R. O’Donnell and Janet C. Wanstall Department of Physiology, University of Queenstand, Brisbane, Australia (Received 12 March 1975; revision received 22 April 1975) SUMMARY 1. A catecholamine P-adrenoreceptor agonist, hexoprenaline, was examined in vitro on five guinea-pig tissues and its potency relative to isoprenaline (as 100) obtained. 2. Hexoprenaline clearly delineated between those tissues classified as containing P,-adrenoreceptors (trachea, hind limb blood vessels and uterus; relative potencies 219, 110 and 76 respectively) and those classified as containing P,-adrenoreceptors (atria and ileum; relative potencies 3.3 and 1.0 respectively). 3. Hexoprenaline differed from some previously studied noncatecholamine P-adrenoreceptor agonists in being only two-fold less potent, relative to isoprena- line, as a vasodilator in perfused hind limb than as a tracheal relaxant. Key words : j3-adrenoreceptors, blood vessels, bronchodilators, guinea-pig, hexo- prenaline, selectivity, trachea. INTRODUCTION In a previous study using in vitro preparations from the guinea-pig, O’Donnell & Wanstall (1974a) examined potential sympathomimetic bronchodilator compounds for their potency as tracheal relaxants (p,-adrenoreceptors), atrial stimulants (P,-adrenoreceptors) and vasodilators in the perfused hind limb (p2-adrenoreceptors). Some resorcinolamines showed selectivity for trachea compared with not only atria but also blood vessels. There is some evidence in dogs in vivo that other noncatecholamines, namely carbuterol (Wardell et al., 1974), and salbutamol and terbutaline (Wasserman & Levy, 1974), display similar select- ivity. If selectivity between respiratory and vascular smooth muscle represents selectivity at the p-adrenoreceptor level, it poses the question whether the P1/p2subclassification (Lands et al., 1967a; Lands, Luduena & Buzzo, 1967b) is too rigid.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]